Veeva Adds New Capabilities to Veeva Site Connect
Latest version offers a streamlined site-centric experience to simplify relationships with study sponsors.
Veeva Systems has announced the newest release of Veeva Site Connect. New capabilities of the solution are headlined by a streamlined site-centric experience that will simplify and standardize site-sponsor relationships.1
The solution offers sponsors and sites a single place to collaborate, automating information flow throughout the lifecycle of a clinical trial. Information flow includes protocols, safety reports, payment letters, and more.
New features of Veeva Site Connect include:
- Expansion beyond document exchange and safety distribution: Veeva Site Connect adds study communications, contacts, payment information, and quick links to sponsor systems to document exchange and safety distribution capabilities.
- Optimized site user interface that’s the same for all trials: Organizing everything sites need in an intuitive site homepage with simple sidebar navigation.
- Accessible for all sites everywhere.
- Simple fixed price implementation to get up and running in two to four months.
“By standardizing how information is shared across all sites in one application with Veeva Site Connect, we aim to save time and effort that can be focused on treating patients,” a clinical operations excellence leader at a top 20 biopharma said in a press release. “Our goal is to eliminate manual handoffs and inefficiencies for faster site start-up, more efficient monitoring, and simplified study closeout.”
Veeva Site Connect is part of Veeva Clinical Platform, which is the provider’s complete solution for patients, sites, and sponsors. According to Veeva, seven of the top 20 biopharmas have already adopted Site Connect.
“I would be ecstatic if all our sponsors use Veeva Site Connect. It gives sites a much more efficient way to collaborate with sponsors, maintain regulatory compliance, and get critical therapies to patients faster,” Alisha Garibaldi, CEO, Skylight Health Research, said in the press release. “The less time we spend doing administrative work in systems, the more time we have to execute trials and help patients.”
Marta Jureczko-Hinzmann, head of global clinical solution services at AstraZeneca added, “By implementing Veeva Site Connect for our safety letter distribution process, we anticipate achieving a significant reduction in manual processing while enhancing oversight and compliance. Sharing safety letters across all sites globally within a single application will allow us to harmonize the entire process across the company and optimize how we allocate valuable resources.”
This announcement from Veeva comes just days before its R&D Quality Summit which will be taking place in Boston, MA, September 9-10.
Reference
1. Major Release of Veeva Site Connect Streamlines Clinical Trial Execution for Sites and Sponsors. News release. Veeva Systems. September 5, 2024. Accessed September 5, 2024. https://www.veeva.com/resources/major-release-of-veeva-site-connect-streamlines-clinical-trial-execution-for-sites-and-sponsors/
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
